Pharma Mega Mergers: Is Bigger Really Better?
This article was originally published in The Pink Sheet Daily
Merck, Wyeth execs say large-scale mergers are indeed necessary to compete in pharma R&D and maintain global reach cost effectively.
You may also be interested in...
Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.
Teetering on the brink of a vast patent cliff, Eli Lilly announced a reorganization and cost-cutting initiative Sept. 14. The program - intended to cut $1 billion in costs by the end of 2010 - is as much about enhancing R&D productivity as creating a leaner organization, according to the company
In a move that could position Pfizer for more drastic measures down the road, the pharma giant has reorganized its development and commercial operations into several business units designed to foster autonomy and financial responsibility in the areas of specialty medicine, primary care and emerging markets